Clinical-stage regenerative medicine company Cambium Bio (ASX:CMB) has announced two key appointments to strengthen its scientific and leadership teams.
Dr. Louis Tong, a distinguished expert in ocular immunology and dry eye disease, has been appointed to Cambium Bio's Scientific Advisory Board.
Dr. Tong is a Senior Consultant at the Singapore National Eye Centre, specialising in Corneal & External Eye Disease, and an Adjunct Associate Professor at the Yong Loo Lin School of Medicine, National University of Singapore.
He is an internationally renowned clinician-scientist with over two decades of experience in ophthalmology, particularly in the areas of dry eye research and treatment development. He has authored more than 150 peer-reviewed publications and holds several patents in ophthalmic therapies.
His wealth of expertise in clinical research will be instrumental in guiding Cambium Bio's ongoing development of novel dry eye disease therapeutics.
Dr. ChiTai Chang has been appointed to Cambium Bio's Board of Directors as a representative of Orient EuroPharma.
Dr. Chang brings extensive experience in the pharmaceutical industry, with a strong background in strategic business development, commercialisation of innovative products, and building partnerships in the healthcare sector.
He has held senior leadership roles at multiple biotechnology firms where he successfully oversaw several drug development programs from early-stage research to regulatory approvals. Dr. Chang is currently the Chief Strategy Officer at Orient EuroPharma and holds a PhD in Chemistry from the University of Pittsburgh. Dr. Chang's proven track record in steering clinical programs to successful market entry will be invaluable as Cambium Bio progresses towards its goal of achieving FDA BLA approval for its lead candidate, Elate Ocular, in dry eye disease.
"We are thrilled to welcome Dr. Louis Tong and Dr. ChiTai Chang to Cambium Bio at this pivotal stage in our company's growth,” Cambium Bio CEO, Karolis Rosickas, said.
“Dr. Tong's deep knowledge of dry eye disease and Dr. Chang's strategic leadership experience in drug development will play crucial roles in our efforts to advance our clinical pipeline and bring Elate Ocular to market."